

An electronic copy of this document is available on the company’s website (www.adocia.com) as well as on the website of the AMF (www.amf-france.org). Hard copies are available upon request at the company’s headquarters located 115, avenue Lacassagne, 69003 Lyon.

The following documents are included in this reference document:

- The 2015 Annual Financial Report including the 2015 Management Report,
- The Chairman of the Executive Board’s report prepared in accordance with article L.225-37 of the French code of commerce as well as the related statutory auditor’s report,
- Information on the fees paid to the Statutory Auditors and the corporate social responsibility.

About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia's insulin formulation portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia's clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four innovative insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapid-acting insulin analog (BioChaperone Combo). Adocia is also developing a concentrated, rapid-acting formulation of human insulin (HinsBet U500).

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro
programs.

Adocia’s extended, early-stage programs include innovative monoclonal antibody formulations, featuring two ongoing collaborations programs with major pharmaceutical companies in the field, and the delivery of anticancer drugs using the proprietary DriveIn® nanotechnology platform.

Adocia aims to deliver “Innovative medicine for everyone, everywhere.”

To learn more about Adocia, please visit us at www.adocia.com

For more information please contact:

<table>
<thead>
<tr>
<th>Adocia</th>
<th>Adocia Press Relations France</th>
<th>Adocia Press Relations Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gérard Soula</td>
<td>ALIZE RP</td>
<td>MC Services AG</td>
</tr>
<tr>
<td>Chairman and CEO</td>
<td>Caroline Carmagnol and Florence</td>
<td>Raimund Gabriel</td>
</tr>
<tr>
<td><a href="mailto:contactinvestisseurs@adocia.com">contactinvestisseurs@adocia.com</a></td>
<td>Portejoie</td>
<td><a href="mailto:raimund.gabriel@mc-services.eu">raimund.gabriel@mc-services.eu</a></td>
</tr>
<tr>
<td>Tél. : +33 4 72 610 610</td>
<td><a href="mailto:caroline@alizerp.com">caroline@alizerp.com</a></td>
<td><a href="mailto:adocia@mc-services.eu">adocia@mc-services.eu</a></td>
</tr>
<tr>
<td></td>
<td><a href="mailto:adocia@alizerp.com">adocia@alizerp.com</a></td>
<td>Tél. : +49 89 210 228 0</td>
</tr>
</tbody>
</table>

Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the ‘Risk Factors’ section of the Reference Document filed with the French Autorité des marchés financiers on April 8, 2016 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.